RT Journal Article
SR Electronic
T1 An exercise-modifiable mitochondrial basis for skeletal muscle insulin resistance in humans
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2025.12.17.25342274
DO 10.64898/2025.12.17.25342274
A1 Nielsen, Tue Leth
A1 Damgaard, Michelle
A1 Andersen, Nicoline Resen
A1 Dunø, Morten
A1 Frederiksen, Anja Lisbeth
A1 van Hall, Gerrit
A1 Sylow, Lykke
A1 Murgia, Marta
A1 Larsen, Steen
A1 Torekov, Signe S.
A1 Vissing, John
A1 Fiorenza, Matteo
YR 2026
UL http://medrxiv.org/content/early/2026/05/22/2025.12.17.25342274.abstract
AB Mitochondrial dysfunction has long been associated with insulin resistance (IR), yet the causal relationship in humans remains unresolved. Here, to probe causality and delineate the underlying molecular mechanisms, we leveraged carriers of the m.3243A>G mtDNA variant as a human genetic model of primary mitochondrial dysfunction linked to diabetes. Deep metabolic phenotyping revealed selective skeletal muscle IR featuring preserved insulin-stimulated Akt-TBC1D4 signaling but blunted mTORC1 activation. Integrated muscle proteomic and bioenergetic profiling demonstrated broad mitochondrial protein depletion, OXPHOS- and complex I-specific deficits, and concomitant AMPKγ2 downregulation. An exercise-based intervention improved muscle insulin sensitivity, partially rescued mitochondrial defects, and increased AMPKγ2 abundance, without altering Akt-TBC1D4 or mTORC1 signaling. An integrative framework linking phenotypic features and exercise-induced remodeling signatures confirmed rescue of m.3243A>G-related molecular alterations and their association with muscle insulin sensitivity. These findings define an exercise-modifiable mitochondrial basis for skeletal muscle IR and identify specific mitochondrial defects as candidate targets for improving glucose homeostasis in common insulin-resistant states.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a project grant from Fabrikant Vilhelm Pedersen og Hustrus Legat on the recommendation of the Novo Nordisk Foundation and by a PhD scholarship from the Research Council at Copenhagen University Hospital-Rigshospitalet.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Research Ethics Committee of the Capital Region of Denmark gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.Fabrikant Vilhelm Pedersen og Hustrus LegatResearch Council at Copenhagen University Hospital–Rigshospitalet, E-22325-19